PEG-MGF offers increased stability and longer experimental observation windows compared to non-PEGylated MGF
Tissue-specific characterization of mitochondrial branched-chain keto acid oxidation using a multiplexed assay platform
* VO (EU) NR
In the CY 2024 OPPS/ASC final rule with comment period, we estimated an ongoing annual national burden of 383,292 hours (54 hours 7,098 hospitals) and an annual national cost of $32,370,571 dollars ($4,560.52 per respondent 7,098 hospitals), which represented a $10,698,069 ($32,370,571$21,672,502) increase over our previous estimated ongoing national annual burden for subsequent years for hospitals to update their standard charge information in the CMS standard template and conform to the data dictionary
North America dominated the market with revenue of USD 1.2 billion in 2025, and is projected to grow at a CAGR of 19.8% through 2034, owing to the presence of a high number of obese and diabetic patients, along with well-developed insurance facilities that promote development of advanced metabolic treatments and regulatory frameworks that make it easier to obtain approval for hormonal combination therapies